Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001015820-25-000072
Filing Date
2025-11-06
Accepted
2025-11-05 20:39:17
Documents
9
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 6-K a2025q3prform6-k.htm 6-K 28578
2 EX-99.1 exhibit9912025q3pressrelea.htm EX-99.1 368957
3 EX-99.2 exhibit992parseacquisition.htm EX-99.2 25666
4 EX-99.3 exhibit9932026syntheticsha.htm EX-99.3 7711
5 EX-99.4 exhibit994ceotransition.htm EX-99.4 5641
6 image_0a.jpg GRAPHIC 3479
7 qiagen_logo1.jpg GRAPHIC 69764
8 qiagen_logoa.jpg GRAPHIC 69764
9 qiagen_logob.jpg GRAPHIC 69764
  Complete submission text file 0001015820-25-000072.txt   729217
Mailing Address HULSTERWEG 82 PL VENLO NETHERLANDS Netherlands 5912 PL
Business Address HULSTERWEG 82 PL VENLO NETHERLANDS Netherlands 5912 PL 31-77-35566-00
QIAGEN N.V. (Filer) CIK: 0001015820 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38332 | Film No.: 251455720
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)